Related Experiment Video
Updated: Jun 25, 2025
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
Published on: March 22, 2016
Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis
Alexandru Scafa Udriște1, Alexandra Cristina Burdușel2, Adelina-Gabriela Niculescu2,3
1Department 4 Cardio-Thoracic Pathology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Insights
Organic nanoparticles show promise for treating cardiovascular diseases (CVDs). Their biocompatibility and drug-loading capacity make them ideal for novel CVD therapies and diagnostics.
Area of Science:
- Nanomedicine
- Cardiovascular Diseases
- Biomaterials
Background:
- Cardiovascular diseases (CVDs) are a leading cause of global mortality, presenting significant challenges in treatment and diagnosis.
- Nanomedicine offers innovative solutions for CVDs through advanced treatments, imaging agents, and diagnostics.
- Current nanomedicine applications in CVDs include enhancing cardiac biomaterials, developing vasculature therapeutics, and improving diagnostic devices.
Purpose of the Study:
- To review recent studies on organic nanoparticles for cardiovascular applications.
- To highlight the potential of nanomedicine in addressing limitations in CVD diagnosis and therapy.
Main Methods:
- Review of the latest research on organic nanoparticles in cardiovascular illness.
- Focus on drug-conjugated polymers, lipid nanoparticles, and micelles.
- Analysis of nanomedicine's role in cardiac biomaterials, vasculature applications, and ex vivo diagnostics.
Main Results:
- Organic nanoparticles demonstrate significant potential in cardiovascular applications.
- Biocompatibility and drug integration capabilities are key advantages.
- Nanoparticle-based approaches can enhance cardiac function and vascular treatments.
Conclusions:
- Organic nanoparticles represent a promising therapeutic strategy for cardiovascular diseases.
- Their properties offer improved biocompatibility and drug delivery for CVD management.
- Further research into organic nanoparticles could revolutionize cardiovascular medicine.
Abstract:
Cardiovascular diseases (CVDs), the world's most prominent cause of mortality, continue to be challenging conditions for patients, physicians, and researchers alike. CVDs comprise a wide range of illnesses affecting the heart, blood vessels, and the blood that flows through and between them. Advances in nanomedicine, a discipline focused on improving patient outcomes through revolutionary treatments, imaging agents, and ex vivo diagnostics, have created enthusiasm for overcoming limitations in CVDs' therapeutic and diagnostic landscapes. Nanomedicine can be involved in clinical purposes for CVD through the augmentation of cardiac or heart-related biomaterials, which can be functionally, mechanically, immunologically, and electrically improved by incorporating nanomaterials; vasculature applications, which involve systemically injected nanotherapeutics and imaging nanodiagnostics, nano-enabled biomaterials, or tissue-nanoengineered solutions; and enhancement of sensitivity and/or specificity of ex vivo diagnostic devices for patient samples. Therefore, this review discusses the latest studies based on applying organic nanoparticles in cardiovascular illness, including drug-conjugated polymers, lipid nanoparticles, and micelles. Following the revised information, it can be concluded that organic nanoparticles may be the most appropriate type of treatment for cardiovascular diseases due to their biocompatibility and capacity to integrate various drugs.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...